Alteogen Records Record High 2025 Earnings: Revenue Surges 117%

South Korean bio-pharmaceutical company Alteogen announced record-breaking financial results for 2025, reporting a revenue of 202.1 billion Korean won and an operating profit of 114.8 billion Korean won. This represents a significant increase compared to 2024, with revenue up 117% and operating profit soaring 275%. The company’s operating profit margin also improved, rising from 33% to 57%.

Key Drivers of Growth

The substantial gains are largely attributed to revenue generated from licensing deals related to Alteogen’s Hybrozyme platform technology, which facilitates the dissolving of hyaluronic acid found in the skin. Specifically, the results include income from the licensing agreement with AstraZeneca finalized in March of last year, as well as milestone payments from the U.S.-based Merck (MSD) for the subcutaneous injection formulation ‘Keytruda CureX’ following approvals in the United States and Europe.

Additional revenue streams came from royalty payments on sales of ‘Ankuta,’ a Herceptin biosimilar sold by Chinese partner Chiroje Yak, and from the supply of ALT-B4.

Did You Know? Alteogen’s Hybrozyme platform has been successfully commercialized with three products currently on the market: Tergazyme, Keytruda CureX, and Ankuta.

Looking Ahead: 2026 and Beyond

Alteogen anticipates further growth in 2026, with the expected J-code designation for Keytruda CureX in April simplifying insurance claims and potentially expanding its market reach. The company believes that increased sales will trigger additional milestone payments. Growing prescription rates for its own enzyme product, ‘Tergazyme,’ which dissolves hyaluronic acid, are expected to contribute to revenue growth.

The Hybrozyme platform has demonstrated its technological capabilities and safety through Keytruda CureX, Alteogen’s first commercialized product. This success has spurred expanded discussions with potential partners, with some conversations progressing towards potential contracts. A recent agreement with GSK subsidiary Tesaro is seen as a starting point for further partnerships.

Expert Insight: The success of Alteogen’s Hybrozyme platform highlights the growing importance of innovative drug delivery technologies in the biopharmaceutical industry. The ability to streamline processes like insurance claims, as with the anticipated J-code for Keytruda CureX, can significantly impact market access and adoption.

Alteogen CEO Tae-yeon Jeon stated that 2025 was a “meaningful year” as the Hybrozyme platform technology entered commercialization through partner MSD, and anticipates that the results of this commercialization will become more visible through milestone payments in 2026.

The company is also anticipating the commercialization of ‘Iruxevi,’ a biosimilar to Eylea, within the year, following its approval by the European Commission in the latter half of 2025.

Alteogen has set a long-term goal to expand its portfolio to include more than nine commercialized products by 2030, encompassing both its own products and those resulting from technology licensing agreements.

Frequently Asked Questions

What is the Hybrozyme platform?

The Hybrozyme platform is Alteogen’s technology that facilitates the dissolving of hyaluronic acid, found in the skin.

Which companies has Alteogen partnered with?

Alteogen has partnered with AstraZeneca, Merck (MSD), Chiroje Yak, GSK subsidiary Tesaro, and is anticipating commercialization with Iruxevi.

What are Alteogen’s long-term goals?

Alteogen aims to have more than nine commercialized products by 2030, including both its own products and those developed through technology licensing agreements.

As Alteogen continues to expand its partnerships and product pipeline, what role do you think innovative drug delivery systems will play in the future of biopharmaceutical development?